Early Results Dampen Outlook for Experimental COVID-19 Treatment

A potential coronavirus treatment called remdesivir entered a clinical trial in February after positive anecdotal reports from the first patients treated with the experimental antiviral. The company that owns remdesivir, Gilead Sciences (NASDAQ:GILD), hasn't released any official data from the ongoing study but we recently received an unofficial preview that's less than encouraging.